Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma

Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberto, Michela, Bassanelli, Maria, Iannicelli, Elsa, Giacinti, Silvana, D'Antonio, Chiara, Aschelter, Anna Maria, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698998/
https://www.ncbi.nlm.nih.gov/pubmed/26798533
http://dx.doi.org/10.1155/2015/629046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698998/
https://www.ncbi.nlm.nih.gov/pubmed/26798533
http://dx.doi.org/10.1155/2015/629046

Ejemplares similares